Search Results - "Skaltsa, K."

Mapping Fact-P To EQ-5D In Metastatic Castration-Resistant Prostate Cancer (MCRPC): Performance Of A Previously Developed Algorithm When Applied On A Sample With A Different Disease Stage by Ivanescu, C, Longworth, L, Skaltsa, K, Holmstrom, S

Get full text

Decision Drivers For Brazil: An Analysis of Conitec Recommendations by Kreeftmeijer, J, Skaltsa, K, Palazzolo, D

Get full text

Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC) by Ghatnekar, O, Nørgaard, K, Skaltsa, K

Get full text

An Archetype For Classification and Comparison of Hta Activities in Latin America by Skaltsa, K, Allen, N, Van, Engen A, Blogg, K

Get full text

Do health technology agencies accept methods for dealing with treatment switching? by Maervoet, J, Skaltsa, K, Ivanescu, C, Van Engen, A

Get full text

Immature Survival Data From Early Trial Termination – Theory and Hta Practice by Pruefert, A, Skaltsa, K, Maervoet, J, Van, Engen A

Get full text

Two-Way Sensitivity Analysis: Showing the Impact of Correlated Parameters in Cost-Effectiveness Analyses by Heemstra, L, Skaltsa, K, Van Engen, A

Get full text

Adjusting overall Survival Estimates for Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer by Naidoo, S, Ivanescu, C, Skaltsa, K, Phung, D, Holmstrom, S, Latimer, N

Get full text

Health Technology Assessment (Hta) Activity Worldwide During 2012 And 2013: Main Trends by Skaltsa, K, Heemstra, L, Tao, C, Van Engen, A

Get full text

Dealing with Zero Cells in Sparse Networks in Bayesian Network Meta-Analysis by Ivanescu, C, Skaltsa, K, Heemstra, L, Van Engen, A

Get full text

PHS65 Mapping the Disease-Specific FACT-P to the Preference-Based EQ-5D in Castration-Resistant Prostate Cancer by Ivanescu, C, Skaltsa, K, Holmstrom, S

Get full text

PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer by Duch, J, Fuster, D, Muñoz, M, Fernández, P L, Paredes, P, Fontanillas, M, Skaltsa, K, Domènech, B, Lomeña, F, Pons, F

“…The aim of this paper was to prospectively evaluate FDG PET/CT in the assessment of metabolic response to neoadjuvant chemotherapy and correlation with tumor…”
Get full text

PNS250 How to Deal with COVID-19-Related Intercurrent Events on Trial Estimands for Patient-Reported Outcomes (PRO) Objectives by Skaltsa, K., Ivanescu, C., Reaney, M.

Get full text

PR2 FATIGUE: ITS USE ACROSS TRIALS FOR MULTIPLE CONDITIONS: REGULATORY SUCCESS by Skaltsa, K., Meyers, O., Sánchez Trullàs, K.

Get full text

PCN486 REGULATORY SUCCESS IN LABELLING HRQOL AND SYMPTOMS FOR NSCLC THERAPIES by Corredoira, L., Meyers, O., Skaltsa, K.

Get full text

PRM26 - TIME TO DETERIORATION (TTD) IN HEALTH RELATED QUALITY OF LIFE (HRQOL) IN NSCLC PATIENTS: A REVIEW OF DEFINITIONS by Skaltsa, K, Casamayor, M, Ivanescu, C

Get full text

PCR22 Standardizing Pro-CTCAE Analyses and Output: Must Have, Helpful to Have, and Easy to Understand by Skaltsa, K, Shaw, J, Hawryluk, E, Bean, SE, Reaney, M

Get full text

PHP249 - Acceptance of Population-Adjusted Indirect Treatment Comparison Methods In Nice Assessments by Ivanescu, C, Skaltsa, K, Kráľ, P

Get full text

Acceptance of Population-Adjusted Indirect Treatment Comparison Methods In Nice Assessments by Ivanescu, C, Skaltsa, K, Kráľ, P

“…OBJECTIVES: Guidelines for applying methods for population-adjusted ITC, e.g. matching adjusted indirect comparisons (MAIC) and simulated treatment comparisons…”
Get full text

PHP209 - Decision Drivers For Brazil: An Analysis of Conitec Recommendations by Kreeftmeijer, J., Skaltsa, K., Palazzolo, D.

Get full text